Freeline to Present New Data on its Gaucher and Parkinson’s Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease

Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program

LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27^th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

“Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low blood counts and chronic fatigue, and many patients continue to experience debilitating symptoms despite treatment with currently approved therapies,” said Michael Parini, Freeline’s Chief Executive Officer. “FLT201, our investigational gene therapy for Gaucher disease, has the potential to deliver better efficacy with a one-time treatment, and we are excited to present new clinical data from our ongoing Phase 1/2 trial in a late-breaking oral presentation at ASGCT. We will also be sharing new data from our Parkinson’s disease research program, which builds on our work in Gaucher disease by leveraging the enhanced stability of our rationally engineered GCase enzyme. Together, these presentations highlight our approach of optimizing every component of our product candidates to unlock the true potential of gene therapy.”

Details of the presentations are below:

Oral Presentation Title: Results from GALILEO-1, a First-In-Human Clinical Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1
Presenter: Dr. Ozlem Goker-Alpan, Lysosomal and Rare Disorders Treatment Center
Session Date and Time: Thursday, May 9, 2024 8:15-8:30 a.m. EDT
Session Title: Late-Breaking Abstracts I
Session Room: Ballroom 3
Late-Breaking Abstract Number: 2

Poster Presentation Title: GBA1-Linked Parkinson’s Disease AAV Gene Therapy
Presenter: Su Kit Chew, PhD, Freeline Therapeutics
Session Date and Time: Thursday, May 9, 2024 12:00-7:00 p.m. EDT
Session Title: Neurologic Diseases
Presentation Room: Exhibit Hall
Final Abstract Number: 1117

Additional details on the meeting can be found at the ASGCT 27th Annual Congress website. The presentation materials will be available on the News & Events section of Freeline’s website following presentation at the ASGCT Annual Meeting.